ArticleClinics (Sao Paulo, Brazil)2026
Preliminary analysis of chromatin accessibility in osteosarcoma tissues.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is highly invasive, metastatic, and lacks effective therapies, leading to poor prognosis. This study aims to dissect the core epigenetic features of OS from the perspective of chromatin accessibility to elucidate its pathogenesis and identify novel therapeutic targets. ATAC-seq was used to map the global chromatin accessibility profiles of OS tissues versus normal controls. We identified OS-specific aberrantly accessible chromatin regions and delineated enriched transcription factor binding motifs. Key transcription factors were validated by Western blotting and flow cytometry. Notably, in regions with enhanced accessibility, the binding probability of AP-1 family members (including Atf3, Fra1, Fra2, JunB, BATF, AP-1, Jun-AP1, Bach2, and CTCF) was significantly elevated. Further analysis indicates that JunB can inhibit apoptosis of OS cells and enhance their invasive ability, suggesting that it may be related to tumor progression. Overall, JunB, as a candidate molecule with potential research value, is worthy of further verification in subsequent in vivo models and clinical samples to determine its feasibility as an intervention target for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.